Related Experiment Videos
[The process of drug development. The "case" of spironolactone]
Stefania De Feo1, Cristina Opasich, Alberto Volpi
1Divisione di Cardiologia, Fondazione S. Maugeri, Clinica del Lavoro e della Riabilitazione, IRCCS, Istituto Scientifico, Pavia.
Insights
Heart failure is a neurohormonal disorder. Spironolactone evolved from a diuretic to a central neurohormonal drug, improving heart failure treatment and patient outcomes.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Context:
- Heart failure pathophysiology has evolved, with current models identifying it as a neurohormonal disorder initiated by cardiac dysfunction.
- Extracardiac alterations drive disease progression, highlighting the role of neuroendocrine activation.
Purpose:
- To trace the evolution of spironolactone's therapeutic role.
- To analyze the advancement of medical knowledge through drug development, focusing on aldosterone and spironolactone.
Summary:
- The paper examines the transformation of spironolactone from a simple diuretic to a neurohormonal agent.
- It details how understanding neuroendocrine systems led to new heart failure treatments, including spironolactone's enhanced efficacy.
Impact:
- Drugs targeting neuroendocrine activation, like spironolactone, significantly reduce heart failure morbidity and mortality.
- The study underscores how analyzing drug development advances medical understanding and therapeutic strategies for heart failure.
Abstract:
In the progressive understanding of the heart failure syndrome different models have followed. Current pathophysiology model suggests that heart failure is a neurohormonal disorder: an abnormality in cardiac function and a disturbance in myocardial contractile force is the initiating event in heart failure, and the clinical expression and progression of the disease occurs as a result of subsequent extracardiac alterations. Treatment with drugs capable of antagonizing the effects of neuroendocrine activation, such as angiotensin-converting enzyme inhibitors, beta-blockers and antialdosterone agents have induced a significant reduction in morbidity and mortality in heart failure patients. The progressive understanding of the circulating homeostasis mechanisms moved from the systemic to the paracrine aspects of the neurohormonal systems and contributed to the development of new drugs. Moreover, the analysis of a drug's development can be an important step in the medical knowledge advancement. In this sense, aldosterone and spironolactone became an interesting "case", which is analyzed in this paper, going through the steps that have promoted the spironolactone from a weak diuretic to a neurohormonal drug and, finally, to a "central" drug.